Previous 10 | Next 10 |
2023-07-21 15:00:10 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial utilization review of JELMYTO (mitomycin) for pyelocalyc...
-- Program to Highlight Topline Results from the Phase 3 ATLAS and Pivotal ENVISION Clinical Trials -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that i...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial utilization review of JELMYTO ® (mitomycin) for...
2023-05-11 15:25:06 ET Urogen Pharma Ltd (URGN) Q1 2023 Earnings Conference Call May 11, 2023, 10:00 ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Jeffre...
2023-05-11 08:21:14 ET UroGen Pharma press release ( NASDAQ: URGN ): Q1 GAAP EPS of -$1.30 beats by $0.01 . Revenue of $17.19M (+26.8% Y/Y) beats by $0.1M . Cash & Cash Equivalents: As of March 31, 2023, cash, cash equivalents and marketable securities tota...
Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech compan...
Conference Call and Webcast Scheduled for Thursday, May 11, 2023, at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2023 fi...
New Retrospective Study Presented at AUA 2023 Reports Use of JELMYTO in Treating Patients with Upper Tract Urothelial Cancer After Complete Endoscopic Ablation UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that trea...
2023-05-01 12:41:33 ET Urogen Pharma ( NASDAQ: URGN ) rose 8% amid takeover speculation for the biotech firm focused on bladder cancer. Urogen ( URGN ) is said to have hired investment bank Centerview Partners after receiving a takeover offer for $17 a share, according...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...